Neuregen Therapeutics was founded in December 2021，dedicated to developing novel therapeutic products based on its proprietary in vivo cell reprogramming (in situ cell transdifferentiation) technology. The company was founded by a team of neuroscientists, ophthalmologists, CGT experts, and seasoned professionals from the biopharmaceutical industry.

The current pipeline focuses on therapeutic products for CNS tumors and degenerative blinding ocular diseases, with the plan to steadily expand into broader therapeutic areas of oncology, regenerative medicine and healthy aging.